19 October 2015 - The agenda for the 21 October 2015 TC meeting is now available. The Commission will consider the following technologies:

• 5-aminolevulinic acid hydrochloride (Ameluz) - new medicine
• Nivolumab (Opdivo) - new medicine
• Pembrolizumab (Keytruda) - new medicine
• Lenvatinib mesylate (Lenvima) - new medicine
• Imiquimod (Zyclara) - new formulation
• Naloxegol oxalate (Moventig) - new medicine

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-10/ordre_du_jour_commission_transparence_21102015.pdf